Kingston R D, Fielding J W, Palmer M K
Department of Clinical Studies, Trafford General Hospital, Manchester, UK.
Int J Colorectal Dis. 1993 Jul;8(2):111-5. doi: 10.1007/BF00299339.
Analysis of data from a randomised trial of adjuvant razoxane involving 603 patients with colo-rectal cancer having curative surgery is reported. The results show that razoxane was ineffective but peri-operative subcutaneous heparin treatment apparently conferred a statistically significant improvement in survival at 5 years, or equivalently a reduction in the risk of death. This beneficial effect is apparent in both razoxane treated and control patients and is not explained by demonstrable differences between heparin and non-heparin treated patients in the distribution of known prognostic factors. Adjustment for these factors slightly increased the apparent magnitude of the beneficial effect.
报告了一项关于辅助使用丙亚胺的随机试验的数据分析，该试验涉及603例接受根治性手术的结肠癌患者。结果显示丙亚胺无效，但围手术期皮下肝素治疗在5年生存率方面显然有统计学上的显著改善，或者等效地降低了死亡风险。这种有益效果在接受丙亚胺治疗的患者和对照组患者中均明显存在，并且不能通过肝素治疗组和非肝素治疗组在已知预后因素分布上的可证明差异来解释。对这些因素进行调整后，有益效果的明显程度略有增加。
